UNASSIGNED: In the STAM™ murine model of NASH, five groups were studied for 8 weeks: (1) vehicle (RO water), (2) AFO-202 beta-glucan; (3) N-163 beta-glucan, (4) AFO-202+N-163 beta-glucan, and (5) telmisartan (standard pharmacological intervention). Evaluation of biochemical parameters in plasma and hepatic histology including Sirius red staining and F4/80 immunostaining were performed.
UNASSIGNED: AFO-202 beta-glucan significantly decreased inflammation-associated hepatic cell ballooning and steatosis. N-163 beta-glucan decreased fibrosis and inflammation significantly (P value < 0.05). The combination of AFO-202 with N-163 significantly decreased the NAFLD Activity Score (NAS) compared with other groups.
UNASSIGNED: This preclinical study supports the potential of N-163 and AFO-202 beta-glucans alone or in combination as potential preventive and therapeutic agent(s), for NASH.
■在NASH的STAM™鼠模型中,五组研究8周:(1)载体(RO水),(2)AFO-202β-葡聚糖;(3)N-163β-葡聚糖,(4)AFO-202+N-163β-葡聚糖,和(5)替米沙坦(标准药物干预)。进行血浆和肝组织学中的生化参数评估,包括天狼星红染色和F4/80免疫染色。
■AFO-202β-葡聚糖显著降低了炎症相关的肝细胞膨胀和脂肪变性。N-163β-葡聚糖显著降低纤维化和炎症(P<0.05)。与其他组相比,AFO-202与N-163的组合显著降低NAFLD活性评分(NAS)。
■这项临床前研究支持N-163和AFO-202β-葡聚糖单独或联合作为潜在的预防和治疗剂的潜力,对于NASH。